Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price dropped 8.2% during trading on Monday . The stock traded as low as GBX 16 and last traded at GBX 16.89. Approximately 4,823,857 shares were traded during trading, an increase of 146% from the average daily volume of 1,962,216 shares. The stock had previously closed at GBX 18.40.
Scancell Trading Down 4.7%
The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The business’s fifty day simple moving average is GBX 19.56 and its two-hundred day simple moving average is GBX 14.68. The stock has a market capitalization of £173.10 million, a P/E ratio of -30.33 and a beta of 0.71.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Recommended Stories
- Five stocks we like better than Scancell
- 3 ETFs Offering Exposure to Latin America’s Stock Market Rally
- Could Apple’s China Play Be the Answer to Its Memory Pressure Problem?
- 3 Charts That Could Change the Course of Summer Trading
- Burger King’s Turnaround Is Putting Restaurant Brands Back in Focus
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
